Expression of Merkelcell polyomavirus (MCPyV) large T-antigen in Merkel cell carcinoma lymph node metastases predicts poor outcome

PLoS One. 2017 Aug 1;12(8):e0180426. doi: 10.1371/journal.pone.0180426. eCollection 2017.

Abstract

Background: The aim of this study was to determine the prevalence of MCPyV in Merkel cell carcinoma (MCC) primaries versus lymph node metastasis and to evaluate possible prognostic factors.

Methods: Samples of MCC primaries and lymph node metastases were stained immunohistochemically for the MCPyV large T-antigen and expression was compared to patients´ clinical outcome.

Results: 41 MCC patients were included. 33 (61%) out of 54 specimens were MCPyV-positive in the immunohistochemistry. 15 (47%) out of 32 primary tumors were positive compared to 18 (82%) out of 22 lymph node metastases. Eleven patients with positive polyomavirus expression died from the carcinoma compared to 4 patients without virus expression. Cox regression analysis showed worse disease-free survival in patients with MCPyV compared to virus-negative lymph nodes (p = 0.002).

Conclusions: To our knowledge this is the first study to describe a negative prognostic effect of the MCPyV expression in lymph node metastasis in MCC patients.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antigens, Viral, Tumor / metabolism*
  • Carcinoma, Merkel Cell / pathology*
  • Carcinoma, Merkel Cell / virology
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic
  • Gene Expression Regulation, Viral
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis
  • Male
  • Merkel cell polyomavirus / genetics
  • Middle Aged
  • Polyomavirus / genetics
  • Polyomavirus Infections / pathology*
  • Prevalence
  • Prognosis
  • Proportional Hazards Models
  • Skin Neoplasms / pathology*
  • Skin Neoplasms / virology
  • Treatment Outcome
  • Tumor Virus Infections / pathology

Substances

  • Antigens, Viral, Tumor

Grants and funding

The authors received no specific funding for this work.